Ceranib-2|cas:1402830-75-4|西域试剂

Ceranib-2,99.25%

产品编号：Bellancom-116147| CAS NO：1402830-75-4| 分子式：C₂₅H₁₉NO₃| 分子量：381.42

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-116147	￥600.00	杭州北京（现货）
Bellancom-116147	￥1100.00	杭州北京（现货）
Bellancom-116147	￥2300.00	杭州北京（现货）
Bellancom-116147	￥3800.00	杭州北京（现货）
Bellancom-116147	￥6200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Ceranib-2

产品介绍

Ceranib-2 是一种有效的非脂质神经酰胺酶 (ceramidase) 抑制剂，可在 SKOV3 细胞中抑制细胞神经酰胺酶活性，IC₅₀ 为 28 μM。Ceranib-2 可诱导多种神经酰胺物质的积累，降低鞘氨醇和鞘氨醇1-磷酸 (S1P) 的水平，并诱导细胞凋亡 (apoptosis)。抗癌活性。

生物活性

Ceranib-2 is a potent and nonlipid ceramidase inhibitor that inhibits cellular ceramidase activity with an IC₅₀ of 28 μM in SKOV3 cells. Ceranib-2 induces the accumulation of multiple ceramide species, decreases levels of sphingosine and sphingosine-1-phosphate (S1P), and induces cell apoptosis. Anticancer activity.

体外研究

Ceranib-2 (10 nM-10 µM; 72 hours; SKOV3 cells) treatment inhibits cell proliferation and/or survival with an IC₅₀ value of 0.73 μM.
Ceranib-2 (0.75-1.5 µM; 48 hours; SKOV3 cells) treatment causes accumulation of cells in the sub-G1 (apoptosis), G2 and S (0.75 μM only) phases of the cell cycle, concomitant with reductions in the number of cells in G1 phase.
Ceranib-2 produces a dose-dependent decrease in ceramidase activity, with 50% inhibition at 28 μM, induces the accumulation of multiple ceramide species, and decreases levels of sphingosine and S1P.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	SKOV3 cells
Concentration:	10 nM-10 µM
Incubation Time:	72 hours
Result:	Cell proliferation and/or survival were inhibited with an IC₅₀ value of 0.73 μM for Ceranib-2.

Cell Cycle Analysis

Cell Line:	SKOV3 cells
Concentration:	0.75 μM, or 1.5 μM
Incubation Time:	48 hours
Result:	Induced cell-cycle arrest and cell death.

体内研究
(In Vivo)

Ceranib-2 (20-50 mg/kg; intraperitoneal injection; daily for 5 days per week; for 3 weeks; female Balb/c mice) treatment delays tumor growth in a syngeneic tumor model without hematologic suppression or overt signs of toxicity.
Intraperitoneal administration of 50 mg/kg Ceranib-2 results in progressive increases in its circulating levels, reaching a peak plasma concentration of approximately 40 μM at the 2 hr time point. Ceranib-2 appears to be cleared with a half-life of less than 2 hr.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Balb/c mice injected with JC murine mammary adenocarcinoma cells
Dosage:	20 mg/kg or 50 mg/kg
Administration:	Intraperitoneal injection; daily for 5 days per week; for 3 weeks
Result:	Delayed tumor growth in a syngeneic tumor model.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Balb/c mice injected with JC murine mammary adenocarcinoma cells
Dosage:	20 mg/kg or 50 mg/kg
Administration:	Intraperitoneal injection; daily for 5 days per week; for 3 weeks
Result:	Delayed tumor growth in a syngeneic tumor model.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Balb/c mice injected with JC murine mammary adenocarcinoma cells
Dosage:	20 mg/kg or 50 mg/kg
Administration:	Intraperitoneal injection; daily for 5 days per week; for 3 weeks
Result:	Delayed tumor growth in a syngeneic tumor model.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (131.09 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6218 mL	13.1089 mL	26.2178 mL
5 mM	0.5244 mL	2.6218 mL	5.2436 mL
10 mM	0.2622 mL	1.3109 mL	2.6218 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 2.5 mg/mL (6.55 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (6.55 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: 2.5 mg/mL (6.55 mM); Clear solution; Need ultrasonic

此方案可获得 2.5 mg/mL (6.55 mM) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。